Posts in Uncategorized

The GMP Annex 11 Revision: Computerised Systems, Data Integrity and the New AI Annex

EU GMP Annex 11, the rulebook for computerised systems in pharmaceutical manufacturing, dates from 2011 — before cloud computing, software-as-a-service and machine learning were part[…]

Market Access for Obesity Medicines in Europe: The Reimbursement Reckoning

The science of obesity treatment has raced ahead of the systems that pay for it. GLP-1 medicines have transformed clinical expectations, but across Europe reimbursement[…]

AI in the Medicines Lifecycle: What EU Regulators Now Expect

Artificial intelligence has moved from the margins of drug development into the mainstream of discovery, clinical trials, manufacturing and pharmacovigilance. EU regulators have responded with[…]

The EU Supply-Security Rulebook: Medicine Shortages, the ESMP and the Critical Medicines Act

Medicine supply security has become one of the most heavily regulated corners of EU pharmaceutical law — and one of the fastest-moving. Between Regulation (EU)[…]

GMP Inspection Readiness: Preparing Your Site for an EU Inspection

An EU good manufacturing practice (GMP) inspection is not an event to prepare for in the final weeks before an inspector arrives — it is[…]

The IVDR: Extended Deadlines, but No Room for Complacency

The In Vitro Diagnostic Regulation reshaped how diagnostics reach the EU market — and while transition deadlines have been extended, the conditions attached to them[…]

EU MDR: Transition Deadlines and the EUDAMED Shift

The medical device transition has moved from a cliff edge to a staged runway — but the conditions attached to those extensions have already passed,[…]

1 … 24 25 26